{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cranial+Nerve+Injury&page=2",
    "query": {
      "condition": "Cranial Nerve Injury",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cranial+Nerve+Injury&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cranial+Nerve+Injury&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T09:44:33.667Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03941327",
      "title": "Do AxoGuard Implants Decrease Shoulder Disability After Neck Dissections",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Accessory Nerve Injury",
        "Cervical Lymphadenopathy"
      ],
      "interventions": [
        {
          "name": "AxoGuard Nerve Cuff",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-05-01",
      "completion_date": "2020-05-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03941327"
    },
    {
      "nct_id": "NCT02109198",
      "title": "Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Trial)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Active CN-NINM PoNS",
          "type": "DEVICE"
        },
        {
          "name": "Sham CN-NINM PoNS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-06",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2015-06-02",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 2,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109198"
    },
    {
      "nct_id": "NCT00017511",
      "title": "Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Oral Complications",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "cevimeline hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-06",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2012-05-16",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 71,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00017511"
    },
    {
      "nct_id": "NCT07282691",
      "title": "Validation of Clinical Outcome Measures Specific to mTBI-Related Oculomotor Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "MTBI - Mild Traumatic Brain Injury"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Salus University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-04-01",
      "completion_date": "2028-09-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282691"
    },
    {
      "nct_id": "NCT05335980",
      "title": "Nu-V3 Non-Invasive Nerve Stimulation Device Trial for Chronic Pain, Anxiety, Depression, Sleeplessness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pain",
        "Anxiety",
        "Depression",
        "Sleeplessness"
      ],
      "interventions": [
        {
          "name": "Nu-V3",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Nu-Life Solutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-04-13",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-04-20",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05335980"
    },
    {
      "nct_id": "NCT02103894",
      "title": "Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease (AD)",
        "Parkinson's Disease (PD)",
        "Chronic Traumatic Encephalopathy (CTE)",
        "Progressive Supranuclear Palsy (PSP)",
        "Frontal Temporal Dementia (FTD)",
        "Pick's Disease",
        "Tauopathies"
      ],
      "interventions": [
        {
          "name": "[18F]T807 ([18F]MNI-777)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular NeuroImaging",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-02",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02103894"
    },
    {
      "nct_id": "NCT05262361",
      "title": "Persistent Post-Concussion Symptoms With Convergence Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Persistent Post-concussive Symptoms",
        "Convergence Insufficiency",
        "Mild Traumatic Brain Injury",
        "Concussion, Mild",
        "Concussion; Eye"
      ],
      "interventions": [
        {
          "name": "Office-based Vergence and Accommodative Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "New Jersey Institute of Technology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "11 Years to 35 Years"
      },
      "enrollment_count": 112,
      "start_date": "2021-09-01",
      "completion_date": "2026-01-19",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 2,
      "location_summary": "Newark, New Jersey • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05262361"
    },
    {
      "nct_id": "NCT02019927",
      "title": "Electric Stimulation of the Eye to Improve Vision After Trauma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)",
        "Trauma",
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "Transcorneal Electrical Stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2013-07",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019927"
    },
    {
      "nct_id": "NCT00492089",
      "title": "Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Meningioma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Central Nervous System Germ Cell Tumor",
        "Adult Choroid Plexus Tumor",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoma",
        "Adult Grade II Meningioma",
        "Adult Grade III Meningioma",
        "Adult Malignant Hemangiopericytoma",
        "Adult Mixed Glioma",
        "Adult Oligodendroglioma",
        "Adult Papillary Meningioma",
        "Adult Pineocytoma",
        "Malignant Neoplasm",
        "Meningeal Melanocytoma",
        "Radiation Toxicity",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adult Brain Tumor",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage I Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage I Basal Cell Carcinoma of the Lip",
        "Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Lymphoepithelioma of the Nasopharynx",
        "Stage I Lymphoepithelioma of the Oropharynx",
        "Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage I Salivary Gland Cancer",
        "Stage I Squamous Cell Carcinoma of the Hypopharynx",
        "Stage I Squamous Cell Carcinoma of the Larynx",
        "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage I Squamous Cell Carcinoma of the Nasopharynx",
        "Stage I Squamous Cell Carcinoma of the Oropharynx",
        "Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Verrucous Carcinoma of the Larynx",
        "Stage I Verrucous Carcinoma of the Oral Cavity",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Basal Cell Carcinoma of the Lip",
        "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Lymphoepithelioma of the Nasopharynx",
        "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2007-06",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492089"
    },
    {
      "nct_id": "NCT04634383",
      "title": "A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ocular Injury",
        "Optic Nerve Diseases",
        "Photoreceptor Degeneration",
        "Blindness,Acquired"
      ],
      "interventions": [
        {
          "name": "WFMA - wireless floating microelectrode array",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Illinois Institute of Technology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2020-08-20",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-02T09:44:33.667Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634383"
    }
  ]
}